Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MET is overexpressed in microsatellite instability-high gastric carcinoma.
|
30455128 |
2019 |
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Volumetric parameters on <sup>18</sup>F-FDG PET/CT predict the survival of patients with gastric cancer associated with their expression status of c-MET.
|
31395059 |
2019 |
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression of circ-DB and MET in GCa tissues was significantly higher than that in the corresponding adjacent tissues.
|
31799656 |
2019 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
|
30511201 |
2019 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This article reports a case of c-MET gene amplification in advanced gastric cancer with liver metastases.
|
31499745 |
2019 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inactivation of CDH1 and RARB by DNA hypermethylation, and amplification of FGFR and MET, are frequently detected in diffuse type GC.
|
30980196 |
2019 |
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MiR-658, paired box gene 3 (PAX3) and met proto-oncogene (MET) are overexpressed in gastric cancer while PAX3 and MET can be regulated by miRNA.
|
29630524 |
2018 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MACC1, HGF and c-Met might cooperatively participate in the malignant progression of gastric cancer.
|
29435059 |
2018 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MACC1, a transcriptional regulator of MET, was recognized as an oncogene in gastric cancer (GC); however, its transcriptional or post-translational regulation was not clear.
|
29510730 |
2018 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Four c-MET inhibitors were tested to elucidate the dependency on MET pathway in the 49 GC cell lines.
|
29435981 |
2018 |
Stomach Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Overall, our results indicate that prolonged MAPK pathway inhibition could result in acquired resistance which is associated with increased malignant phenotype in KRAS mutant GC and pharmacological targeting c-MET and PI3K/mTOR could overcome this problem.
|
30466782 |
2018 |
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MET amplification and Met overexpression were positively correlated in GC.
|
29790169 |
2018 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In vivo experiments revealed that CAFs-derived HGF promoted tumorigenesis and metastasis of MET-unamplified GC.
|
30158543 |
2018 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In 123 cases with primary and corresponding local recurrent/distant metastatic GC, 3 (2.4%) showed MET positivity in which 2 (66.7%) were discordant (positive conversion).
|
28968267 |
2018 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MET amplification has been clinically credentialed as a therapeutic target in gastric cancer, but the molecular mechanisms underlying sensitivity and resistance to MET inhibitors are still not well understood.
|
28881678 |
2017 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, MET overexpression could serve as a prognostic biomarker and a potential therapeutic target for gastric cancer.
|
28052014 |
2017 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
|
28314274 |
2017 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study describes the prevalence and prognostic value of EGFR and c-MET in a Canadian population of patients undergoing curative intent resection for GC.
|
26125303 |
2017 |
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We then analyzed MET expression and activity in a matched set of FFPE vs. fresh frozen tumor samples consisting of 20 cases of gastric cancer.
|
28836864 |
2017 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overexpression of MET occurs frequently in gastric cancer and has been proposed as a potential predictive biomarker for anti-MET therapy.
|
26690587 |
2016 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Similar results were obtained in additional GC cell lines with amplification of MET or the FGF receptor FGFR2 MKN45 murine xenograft experiments demonstrated the antitumor activity of M-COPA in vivo Taken together, our results offer an initial preclinical proof of concept for the use of M-COPA as a candidate treatment option for MET-addicted GC, with broader implications for targeting the Golgi apparatus as a novel cancer therapeutic approach.
|
27197184 |
2016 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Crizotinib may induce clinically relevant anticancer effects in MET-overexpressed or MET-amplified gastric cancer patients.
|
26404902 |
2016 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation.
|
27437872 |
2016 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MET-positive GCs had a very poor prognosis, with a median survival of 5.4 months and a hazard ratio of 2.126.
|
26033401 |
2016 |
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer.
|
27185371 |
2016 |